BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma X, Liu S, Zhang J, Dong M, Wang Y, Wang M, Xin Y. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol. 2020;20:10. [PMID: 31937252 DOI: 10.1186/s12876-020-1165-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Kriss M, Golden-Mason L, Kaplan J, Mirshahi F, Setiawan VW, Sanyal AJ, Rosen HR. Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development. PLoS One 2020;15:e0236353. [PMID: 32730345 DOI: 10.1371/journal.pone.0236353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Mohamed AA, El-Demery A, Al-Hussain E, Mousa S, Halim AA, Mostafa SM, Abdelghany RS, Mahmoud SM, Elkady MA, Raafat K, Hassnine AA, Omran MM. NAFLD mark: an accurate model based on microRNA-34 for diagnosis of non-alcoholic fatty liver disease patients. J Genet Eng Biotechnol 2021;19:157. [PMID: 34661762 DOI: 10.1186/s43141-021-00257-5] [Reference Citation Analysis]
3 Oses M, Medrano M, Galbete A, Arenaza L, Ruiz JR, Sánchez-Valverde F, Ortega FB, Labayen I. A sociodemographic, anthropometric and lifestyle-based prediction score for screening children with overweight and obesity for hepatic steatosis: The HEPAKID index. Pediatr Obes 2021;16:e12770. [PMID: 33403830 DOI: 10.1111/ijpo.12770] [Reference Citation Analysis]
4 Dionysopoulos G, Kalopitas G, Vadarlis A, Bakaloudi DR, Gkiourtzis N, Karanika E, Tsekitsidi E, Chourdakis M. Can omega-3 fatty acids be beneficial in pediatric NAFLD? A systematic review and meta-analysis. Crit Rev Food Sci Nutr 2022;:1-9. [PMID: 35400251 DOI: 10.1080/10408398.2022.2062589] [Reference Citation Analysis]
5 Toita R, Kang JH. Long-term profile of serological biomarkers, hepatic inflammation, and fibrosis in a mouse model of non-alcoholic fatty liver disease. Toxicol Lett 2020;332:1-6. [PMID: 32579995 DOI: 10.1016/j.toxlet.2020.06.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Muhammad N, Lembede BW, Erlwanger KH. Zingerone Administered Neonatally Prevents the Subsequent Development of High Dietary Fructose-Induced Fatty Liver in Sprague Dawley Rats. J Med Food 2021. [PMID: 33512269 DOI: 10.1089/jmf.2020.0189] [Reference Citation Analysis]
7 Zhou Z, Sang L, Wang J, Song L, Zhu L, Wang Y, Xiao J, Lian Y. Relationships among N,N-dimethylformamide exposure, CYP2E1 and TM6SF2 genes, and non-alcoholic fatty liver disease. Ecotoxicol Environ Saf 2021;228:112986. [PMID: 34794021 DOI: 10.1016/j.ecoenv.2021.112986] [Reference Citation Analysis]
8 Gupta H, Min B, Ganesan R, Gebru YA, Sharma SP, Park E, Won S, Jeong J, Lee S, Cha M, Kwon G, Jeong M, Hyun J, Eom J, Park H, Yoon S, Choi M, Kim D, Suk K. Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role. Biomedicines 2022;10:550. [DOI: 10.3390/biomedicines10030550] [Reference Citation Analysis]
9 Shengir M, Krishnamurthy S, Ghali P, Deschenes M, Wong P, Chen T, Sebastiani G. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome. World J Gastroenterol 2020; 26(44): 7046-7060 [PMID: 33311949 DOI: 10.3748/wjg.v26.i44.7046] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Mertens J, De Block C, Spinhoven M, Driessen A, Francque SM, Kwanten WJ. Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy. Front Pharmacol 2021;12:768576. [PMID: 34759828 DOI: 10.3389/fphar.2021.768576] [Reference Citation Analysis]
11 Wang F, Park JS, Ma Y, Ma H, Lee YJ, Lee GR, Yoo HS, Hong JT, Roh YS. Ginseng Saponin Enriched in Rh1 and Rg2 Ameliorates Nonalcoholic Fatty Liver Disease by Inhibiting Inflammasome Activation. Nutrients 2021;13:856. [PMID: 33807927 DOI: 10.3390/nu13030856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Claus M, Antoni C, Hofmann B. Factors associated with elevated alanine aminotransferase in employees of a German chemical company: results of a large cross-sectional study. BMC Gastroenterol 2021;21:25. [PMID: 33422007 DOI: 10.1186/s12876-021-01601-2] [Reference Citation Analysis]
13 Thong VD, Quynh BTH. Correlation of Serum Transaminase Levels with Liver Fibrosis Assessed by Transient Elastography in Vietnamese Patients with Nonalcoholic Fatty Liver Disease. Int J Gen Med 2021;14:1349-55. [PMID: 33889015 DOI: 10.2147/IJGM.S309311] [Reference Citation Analysis]
14 Manka PP, Kaya E, Canbay A, Syn WK. A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021;66:3676-88. [PMID: 34410573 DOI: 10.1007/s10620-021-07206-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lee LW, Yen JB, Lu HK, Liao YS. Prediction of Nonalcoholic Fatty Liver Disease by Anthropometric Indices and Bioelectrical Impedance Analysis in Children. Child Obes 2021. [PMID: 34265208 DOI: 10.1089/chi.2021.0054] [Reference Citation Analysis]
16 Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021:gutjnl-2020-323202. [PMID: 33632710 DOI: 10.1136/gutjnl-2020-323202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Farrell AM, Magliano DJ, Shaw JE, Thompson AJ, Croagh C, Ryan MC, Howell J. A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study. Sci Rep 2022;12:1956. [PMID: 35121749 DOI: 10.1038/s41598-022-05168-0] [Reference Citation Analysis]
18 Jun BG, Kim M, Shin HS, Yi J, Yi S. Impact of overweight and obesity on the risk of hepatocellular carcinoma: a prospective cohort study in 14.3 million Koreans. Br J Cancer. [DOI: 10.1038/s41416-022-01771-0] [Reference Citation Analysis]
19 Jones GS, Alvarez CS, Graubard BI, McGlynn KA. Agreement Between the Prevalence of Nonalcoholic Fatty Liver Disease Determined by Transient Elastography and Fatty Liver Indices. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31562-7. [PMID: 33227430 DOI: 10.1016/j.cgh.2020.11.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Nachit M, De Rudder M, Thissen JP, Schakman O, Bouzin C, Horsmans Y, Vande Velde G, Leclercq IA. Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models. J Cachexia Sarcopenia Muscle 2021;12:144-58. [PMID: 33244884 DOI: 10.1002/jcsm.12646] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Barritt AS, Watkins S, Gitlin N, Klein S, Lok AS, Loomba R, Schoen C, Reddy KR, Trinh HN, Mospan AR, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. Hepatol Commun 2021;5:938-46. [PMID: 34141981 DOI: 10.1002/hep4.1689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Alswat K, Sanai FM, Al-Hamoudi W, Ismail M, Dahlan Y, AlGhamdi HS, Altraif I, Alalwan A, Babatin MMA, Alqahtani SA. Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry. Diabetes Metab Syndr Obes 2021;14:1167-75. [PMID: 33762835 DOI: 10.2147/DMSO.S300051] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Miazgowski T, Kaczmarkiewicz A, Miazgowski B, Kopeć J. Cardiometabolic health, visceral fat and circulating irisin levels: results from a real-world weight loss study. J Endocrinol Invest 2021;44:1243-52. [PMID: 32892317 DOI: 10.1007/s40618-020-01415-1] [Reference Citation Analysis]
24 Wilson A, Beaton M, Brahmania M. Letter to the Editor: Nonalcoholic Fatty Liver Disease-One Size May Not Fit All. Hepatology 2021;74:528. [PMID: 32965684 DOI: 10.1002/hep.31564] [Reference Citation Analysis]
25 Du X, DeForest N, Majithia AR. Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities. Front Endocrinol (Lausanne) 2021;12:777075. [PMID: 34950105 DOI: 10.3389/fendo.2021.777075] [Reference Citation Analysis]
26 Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. Life (Basel) 2021;11:143. [PMID: 33672864 DOI: 10.3390/life11020143] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Li C, Cui L, Wang X, Yan Z, Wang S, Zheng Y. Using intestinal flora to distinguish non-alcoholic steatohepatitis from non-alcoholic fatty liver. J Int Med Res 2020;48:300060520978122. [PMID: 33327816 DOI: 10.1177/0300060520978122] [Reference Citation Analysis]
28 Perez-Diaz-Del-Campo N, Abete I, Cantero I, Marin-Alejandre BA, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Riezu-Boj JI, Milagro FI, Tur JA, Martinez JA, Zulet MA. Association of the SH2B1 rs7359397 Gene Polymorphism with Steatosis Severity in Subjects with Obesity and Non-Alcoholic Fatty Liver Disease. Nutrients 2020;12:E1260. [PMID: 32365683 DOI: 10.3390/nu12051260] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
29 Congly SE, Shaheen AA, Swain MG. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting. PLoS One 2021;16:e0251741. [PMID: 34019560 DOI: 10.1371/journal.pone.0251741] [Reference Citation Analysis]
30 Oses M, Cadenas-Sanchez C, Medrano M, Galbete A, Miranda-Ferrua E, Ruiz JR, Sánchez-Valverde F, Ortega FB, Cabeza R, Villanueva A, Idoate F, Labayen I. Development of a prediction protocol for the screening of metabolic associated fatty liver disease in children with overweight or obesity. Pediatr Obes 2022;:e12917. [PMID: 35394122 DOI: 10.1111/ijpo.12917] [Reference Citation Analysis]